Specialty pharmaceutical-company United Therapeutics (NASDAQ: UTHR) was an outlier stock in the best way on Wednesday. After reporting quarterly figures showing revenue growth in all of its products, the shares closed the day over 14% higher.
United Therapeutics took in $446.5 million in revenue for its Q2, which was a very healthy 23% higher year over year. Net income also rose handsomely: On a non- GAAP (adjusted) basis, it advanced by 19% to land at $193.5 million, or $4.09 per share.
Image source: Getty Images.
For further details see:
Why United Therapeutics Blasted 14% Higher Today